Tag: Sino Biopharmaceutical
Sino Biopharmaceutical Announces 2020 First Quarterly Results
Revenue was approximately RMB6.22 Billion;
Profit Attributable to Owners of the Parent was approximately RMB862 Million
Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with...
New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the...
Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative R&D driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the...
Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed...
Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the abstracts on...
Sino Biopharm Announces 2019 Annual Results
Revenue Climbs 16.0% to RMB24.23 billion Underlying Profit Up 10.2% to RMB3.13 billion;
Achieves an outstanding R&D performance and obtains 28 production approvals
Sino Biopharmaceutical Limited...
Sino Biopharmaceutical Announces 2018 Third Quarterly Results
Profit Attributable to the Group Increased by Approximately 29.9% to Approximately RMB 2,247,477,000
HONG KONG - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the...